Michael Bigby is a Dermatology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 202 publications with 7,825 citations (h-index 38). By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave
Cc2
Boston, MA 022155400
Telephone
617-667-3753Provider last certified this registry record 20 Jul 2022.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment$11,940openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
41%Corticosteroid41%Clobetasol Propionate51%Betamethasone Diprop Augmented30%Betamethasone Dipropionate20%Part D≥20 patientsDermatology
23.9%Interleukin-4 Receptor alpha Antagonist13.1%Dupixent Syringe100%Part D<11 patientsCorticosteroid10.8%Triamcinolone Acetonide100%Part D≥17 patientsAnti-infectives
22.1%Azole Antifungal9.5%Ketoconazole100%Part D≥16 patientsTetracycline-class Drug6.8%Doxycycline Monohydrate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1991–1995 per NIH RePORTER. The latest:
- USE OF T-CELL HYBRIDOMAS TO STUDY CUTANEOUS IMMUNOLOGY
Massachusetts General Hospital
FY1993R29AR039795
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Time to reconsider the role of sentinel lymph node biopsy in melanoma
Journal of the American Academy of Dermatology
2018 - Hepatitis C Virus and Lichen Planus A Reciprocal Association Determined by a Meta-analysis2016
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”